← Leaderboards
Richard J Smith
University Of Iowa
$33,390,035
Attributed
$42,203,067
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,203,067 · 15
By mechanism
R01$40,923,022 · 8
P50$1,200,645 · 2
R13$79,400 · 5
Top collaborators
- Michael John Schnieders15 shared
- Terry A Braun10 shared
- Thomas L. Casavant10 shared
- Patrick Breheny8 shared
- Carla M Nester8 shared
- Diana I Jalal3 shared
- Joshua M Thurman3 shared
- Jacob James Michaelson1 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Gregory S Hageman$17,947,462
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesGeneticPersonsDeafnessHearing ImpairmentAffectHearingGrantBaseComplexVariantBiologyProteinsFoundationsMutationPhenotypeDiagnosisGenotypeInsightMolecularInheritedGene MutationAreaFamily
Grant awards (93)
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$640,948
R01 · FY2025 · DK
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$579,133
R01 · FY2025 · DC · contact PI
C3 Glomerulopathy -- A Collaborative Study$577,430
R01 · FY2025 · DK · contact PI
Core C: Developmental Genomics-Epigenetics Core$240,129
P50 · FY2025 · HD · contact PI
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$634,659
R01 · FY2024 · DK
C3 Glomerulopathy -- A Collaborative Study$629,064
R01 · FY2024 · DK · contact PI
Non-Syndromic Hearing Loss A Collaborative Study$622,939
R01 · FY2024 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$615,513
R01 · FY2024 · DC · contact PI
Core C: Developmental Genomics-Epigenetics Core$240,129
P50 · FY2024 · HD · contact PI
C3 Glomerulopathy -- A Collaborative Study$655,274
R01 · FY2023 · DK · contact PI
The Alternative Pathway of Complement: A Potential Contributor to Adverse Outcomes in CKD$629,433
R01 · FY2023 · DK
Non-Syndromic Hearing Loss A Collaborative Study$622,939
R01 · FY2023 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$615,513
R01 · FY2023 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss - Its Genetic Diagnosis and Treatment$471,223
R01 · FY2023 · DC · contact PI
Core C: Developmental Genomics-Epigenetics Core$240,129
P50 · FY2023 · HD · contact PI
Non-Syndromic Hearing Loss A Collaborative Study$622,939
R01 · FY2022 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$615,513
R01 · FY2022 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss - Its Genetic Diagnosis and Treatment$471,223
R01 · FY2022 · DC · contact PI
Core C: Developmental Genomics-Epigenetics Core$240,129
P50 · FY2022 · HD · contact PI
C3 Glomerulopathy -- A Collaborative Study$627,373
R01 · FY2021 · DK · contact PI
Non-Syndromic Hearing Loss A Collaborative Study$622,939
R01 · FY2021 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$508,845
R01 · FY2021 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss - Its Genetic Diagnosis and Treatment$486,171
R01 · FY2021 · DC · contact PI
Core C: Developmental Genomics-Epigenetics Core$240,129
P50 · FY2021 · HD · contact PI
Non-Syndromic Hearing Loss â A Collaborative Study$636,564
R01 · FY2020 · DC · contact PI
C3 Glomerulopathy -- A Collaborative Study$627,373
R01 · FY2020 · DK · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss - Its Genetic Diagnosis and Treatment$606,990
R01 · FY2020 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$508,845
R01 · FY2020 · DC · contact PI
12th Conference on the Molecular Biology of Hearing and Deafness$35,000
R13 · FY2020 · DC · contact PI
C3 Glomerulopathy -- A Collaborative Study$627,373
R01 · FY2019 · DK · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss - Its Genetic Diagnosis and Treatment$606,990
R01 · FY2019 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$480,576
R01 · FY2019 · DC · contact PI
C3 Glomerulopathy -- A Collaborative Study$627,373
R01 · FY2018 · DK · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$564,086
R01 · FY2018 · DC · contact PI
Non-Syndromic Hearing Loss - A Collaborative Study$523,167
R01 · FY2018 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$53,375
R01 · FY2018 · DC · contact PI
C3 Glomerulopathy -- A Collaborative Study$627,373
R01 · FY2017 · DK · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$564,086
R01 · FY2017 · DC · contact PI
Non-Syndromic Hearing Loss - A Collaborative Study$523,167
R01 · FY2017 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$498,238
R01 · FY2017 · DC · contact PI
Non-Syndromic Hearing Loss - A Collaborative Study$523,167
R01 · FY2016 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$498,238
R01 · FY2016 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$574,693
R01 · FY2015 · DC · contact PI
Non-Syndromic Hearing Loss - A Collaborative Study$563,013
R01 · FY2015 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$493,253
R01 · FY2015 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$606,168
R01 · FY2014 · DC · contact PI
Non-Syndromic Hearing Loss - A Collaborative Study$568,701
R01 · FY2014 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$498,238
R01 · FY2014 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$588,237
R01 · FY2013 · DC · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$534,036
R01 · FY2013 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$510,986
R01 · FY2013 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$637,782
R01 · FY2012 · DC · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$538,365
R01 · FY2012 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$507,024
R01 · FY2012 · DC · contact PI
Optimizing Genetic Testing for Deafness for Clinical Diagnostics$608,130
R01 · FY2011 · DC · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$563,951
R01 · FY2011 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$506,985
R01 · FY2011 · DC · contact PI
A Collaborative Study of Membranoproliferative Glomerulonephritis Type II$245,734
R01 · FY2011 · DK · contact PI
Fourth Dense Deposit Disease Focus Group Meeting$8,000
R13 · FY2011 · DK · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$575,243
R01 · FY2010 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$516,525
R01 · FY2010 · DC · contact PI
A Collaborative Study of Membranoproliferative Glomerulonephritis Type II$248,216
R01 · FY2010 · DK · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$595,663
R01 · FY2009 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$507,899
R01 · FY2009 · DC · contact PI
A Collaborative Study of Membranoproliferative Glomerulonephritis Type II$250,723
R01 · FY2009 · DK · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$523,161
R01 · FY2008 · DC · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$473,392
R01 · FY2008 · DC · contact PI
A Collaborative Study of Membranoproliferative Glomerulonephritis Type II$252,928
R01 · FY2008 · DK · contact PI
Hinxton Conference of Excellence - Dense Deposit Disease: Therapeutic Options$21,400
R13 · FY2008 · DK · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$468,588
R01 · FY2007 · DC · contact PI
A Collaborative Study of Membranoproliferative Glomerulonephritis Type II$278,590
R01 · FY2007 · DK · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$471,547
R01 · FY2006 · DC · contact PI
Autosomal Dominant Non-Syndromic Hearing Loss$386,912
R01 · FY2006 · DC · contact PI
Otosclerosis-A Molecular Genetic Study$296,020
R01 · FY2006 · DC · contact PI
Hinxton Retreat Workshop on Membranoproliferative Glomerulonephritis Type II$10,000
R13 · FY2006 · DK · contact PI
Non-Syndromic Hearing Loss -- A Collaborative Study$471,920
R01 · FY2005 · DC
Autosomal Dominant Non-Syndromic Hearing Loss$384,513
R01 · FY2005 · DC
Otosclerosis-A Molecular Genetic Study$303,144
R01 · FY2005 · DC
Non-Syndromic Hearing Loss: A Collaborative Study$461,271
R01 · FY2004 · DC
Autosomal Dominant Non-Syndromic Hearing Loss$371,972
R01 · FY2004 · DC
Otosclerosis-A Molecular Genetic Study$303,144
R01 · FY2004 · DC
Membranoproliferative Glomerulonephritis Workshop$5,000
R13 · FY2004 · DK
Autosomal Dominant Non-Syndromic Hearing Loss$361,434
R01 · FY2003 · DC
NON-SYNDROMIC HEARING LOSS--A COLLABORATIVE STUDY$341,370
R01 · FY2003 · DC
Otosclerosis-A Molecular Genetic Study$303,144
R01 · FY2003 · DC
Autosomal Dominant Non-Syndromic Hearing Loss$549,552
R01 · FY2002 · DC
NON-SYNDROMIC HEARING LOSS--A COLLABORATIVE STUDY$331,483
R01 · FY2002 · DC
Otosclerosis-A Molecular Genetic Study$303,144
R01 · FY2002 · DC
NON-SYNDROMIC HEARING LOSS--A COLLABORATIVE STUDY$524,613
R01 · FY2001 · DC
AUTOSOMAL DOMINANT NONSYNDROMIC HEARING LOSS$310,871
R01 · FY2001 · DC
AUTOSOMAL DOMINANT NONSYNDROMIC HEARING LOSS$49,606
R01 · FY2001 · DC
NON-SYNDROMIC HEARING LOSS--A COLLABORATIVE STUDY$513,213
R01 · FY2000 · DC
AUTOSOMAL DOMINANT NONSYNDROMIC HEARING LOSS$301,873
R01 · FY2000 · DC